嵌合抗原受体
染色质
IRF4公司
造血
表观遗传学
生物
癌症研究
T细胞
细胞
免疫学
细胞生物学
干细胞
转录因子
遗传学
基因
免疫系统
作者
Penglei Jiang,Zhaoru Zhang,Yongxian Hu,Zuyu Liang,Yingli Han,Xia Li,Xin Zeng,Hao Zhang,Meng Zhu,Jian Dong,He Huang,Pengxu Qian
出处
期刊:Leukemia
[Springer Nature]
日期:2022-08-12
卷期号:36 (11): 2656-2668
被引量:26
标识
DOI:10.1038/s41375-022-01676-0
摘要
Chimeric antigen receptor T cells (CAR-T) therapy has achieved remarkable therapeutic success in treating a variety of hematopoietic malignancies. However, the high relapse rate and poor in vivo persistence, partially caused by CAR-T cell exhaustion, are still important barriers against CAR-T therapy. It remains largely elusive on the mechanisms of CAR-T exhaustion and how to attenuate exhaustion to achieve better therapeutic efficacy. In this study, we initially observed that CAR-T cells showed rapid differentiation and increased exhaustion after co-culture with tumor cells in vitro, and then performed single-cell ATAC-seq to depict the comprehensive and dynamic landscape of chromatin accessibility of CAR-T cells during tumor cell stimulation. Analyses of differential chromatin accessible regions and motif accessibility revealed that TFs were distinct in each cell type and reconstituted a coordinated regulatory network to drive CAR-T exhaustion. Furthermore, we performed scATAC-seq in patient-derived CAR-T cells and identified BATF and IRF4 as pivotal regulators in CAR-T cell exhaustion. Finally, knockdown of BATF or IRF4 enhanced the killing ability, inhibited exhaustion, and prolonged the persistence of CAR-T cells in vivo. Together, our study unraveled the epigenetic regulatory mechanisms of CAR-T exhaustion and provided new insights into CAR-T engineering to achieve better clinical treatment benefits.
科研通智能强力驱动
Strongly Powered by AbleSci AI